Table 3.
Outcome data of randomized controlled trials included in the meta-analysis
|
Study |
Antioxidant group |
Control group |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| |
No. of patients (n) |
No. of PEP (n) |
PEP stratified by severity |
No. of patients (n) |
No. of PEP (n) |
PEP stratified by severity |
||||
| Mild | Moderate | Severe | Mild | Moderate | Severe | |||||
| Wollschläger et al.
[21] |
20 |
2 |
NA |
NA |
NA |
20 |
3 |
NA |
NA |
NA |
| Budzyńska et al.
[22] |
99 |
12 |
9 |
2 |
1 |
101 |
8 |
5 |
3 |
0 |
| Lavy et al.
[23] |
141 |
14 |
10 |
4 |
0 |
180 |
17 |
9 |
4 |
4 |
| Katsinelos et al.
[24] |
124 |
15 |
8 |
7 |
0 |
125 |
12 |
7 |
5 |
0 |
| Katsinelos et al.
[25] |
125 |
4 |
4 |
0 |
0 |
118 |
21 |
8 |
11 |
2 |
| Mosler et al.
[26] |
355 |
46 |
28 |
16 |
2 |
346 |
42 |
24 |
16 |
2 |
| Milewski et al.
[27] |
55 |
4 |
NA |
NA |
NA |
51 |
6 |
NA |
NA |
NA |
| Kapetanos et al.
[28] |
158 |
9 |
6 |
1 |
2 |
162 |
5 |
4 |
0 |
1 |
| Romagnuolo et al.
[29] |
293 |
16 |
8 |
6 |
2 |
293 |
12 |
4 |
6 |
2 |
| Martinez et al.
[30] |
85 |
2 |
NA |
NA |
NA |
85 |
8 |
NA |
NA |
NA |
| Abbasinazari et al. [31] | 29 | 3 | 2 | 1 | 0 | 45 | 5 | 3 | 2 | 0 |
ERCP = endoscopic retrograde cholangiopancreatography, PEP = post-ERCP pancreatitis, NA = not available.